METABOLIK SINDROMLI BEMORLARDA PSORIAZNING KLINIK-PATOGENETIK XUSUSIYATLARI VA SHAXSIYLASHTIRILGAN DAVOLASHNI TAKOMILLASHTIRISH YO‘LLARI

Maqola yon paneli

pdf (ruscha)
Nashr qilingan: 2026-01-05
DOI: https://doi.org/10.66073/researchfocus.v4i12.1941
Kalit so‘zlar:
psoriaz, metabolik sindrom, tizimli yallig'lanish, IL-17A, TNF-α, insulinorezistentlik, HOMA-IR, biologik terapiya, shaxsiylashtirilgan tibbiyot, PASI

Maqolaning asosiy mazmuni

Bozorova Zarina Xamza qizi
Samarqand davlat tibbiyot universiteti
Narzikulov Rustam Mardonovich

Abstrak

Dolzarbligi. Psoriaz surunkali immun-yallig'lanish kasalligi bo'lib, ko'pincha metabolik sindrom (MS) bilan birga kechadi; bu teri jarayonining og'irroq kechishiga, tizimli yallig'lanishning kuchayishiga va standart terapiya samaradorligining pasayishiga olib keladi. Psoriaz va MS patogenetik mexanizmlarining umumiyligi — IL-23/Th17 o'qining faollashuvi, proyallig'lanish sitokinlarining ortiqchaligi, insulinorezistentlik va adipokin profilining buzilishi — davolashda shaxsiylashtirilgan yondashuvlarni izlashni dolzarb qiladi. Tadqiqot maqsadi. Metabolik sindromli bemorlarda psoriazning klinik-patogenetik xususiyatlarini o'rganish va shaxsiylashtirilgan terapevtik strategiyaning samaradorligini standart davolash bilan taqqoslab baholash. Materiallar va usullar. Blyashkali psoriazli 112 bemorda prospektiv tadqiqot o'tkazildi; ular ikki guruhga bo'lindi: asosiy guruh (n = 58) — psoriaz va MS bo'lgan bemorlar, nazorat guruhi (n = 54) — MS bo'lmagan bemorlar. PASI, BSA, DLQI, uglevod va lipid almashinuvi ko'rsatkichlari, TNF-α, IL-6, IL-17A, CRP, insulin, HOMA-IR darajalari baholandi. Terapiya samaradorligi PASI-50/75/90 mezonlari bo'yicha tahlil qilindi. Styudent t-mezoni, Mann–Uitni U-mezoni va χ² qo'llanildi. Natijalar. MS bo'lgan bemorlarda psoriaz og'irligining yuqoriroq ko'rsatkichlari (PASI 19.4 ± 6.2 ga qarshi 13.7 ± 4.8; p < 0.01), zararlanishlarning kengroq tarqalganligi (BSA 24.6 ± 8.1 ga qarshi 16.3 ± 5.7; p < 0.01) va hayot sifatining ko'proq pasayishi (DLQI 17.2 ± 5.4 ga qarshi 11.6 ± 4.2; p < 0.01) aniqlandi. TNF-α, IL-17A, CRP va HOMA-IR ning ishonchli oshishi (p < 0.01), shuningdek PASI ↔ IL-17A (r = 0.61), PASI ↔ HOMA-IR (r = 0.54) korrelyatsiyalari qayd etildi. Shaxsiylashtirilgan terapiya standart terapiyadan ustun keldi: PASI-75 ga erishish 67 % ga qarshi 38 % (p < 0.01), PASI-90 — 41 % ga qarshi 19 % (p < 0.05) ni tashkil etdi. Xulosa. Metabolik sindrom psoriazning klinik kechishini og'irlashtiradi va an'anaviy terapiya samaradorligini pasaytiradi. Metabolik holat, proyallig'lanish sitokinlari darajalari va insulinorezistentlikni hisobga oluvchi shaxsiylashtirilgan yondashuv yaqqolroq terapevtik javob beradi va ushbu toifadagi bemorlarni olib borishning afzal strategiyasi sifatida ko'rib chiqilishi kerak.

Maqola tafsilotlari

Nashr

Jild 4 Nomeri 12 (2025): Research Focus International Scientific Journal. 4-tom, 12-son (2025)

Bo'lim

14.00.00 – Tibbiyot fanlari
Creative Commons litsenziyasi

Ushbu asar Creative Commons Attribution 4.0 International litsenziyasi asosida litsenziyalangan.

Qanday iqtibos keltirish kerak

METABOLIK SINDROMLI BEMORLARDA PSORIAZNING KLINIK-PATOGENETIK XUSUSIYATLARI VA SHAXSIYLASHTIRILGAN DAVOLASHNI TAKOMILLASHTIRISH YO‘LLARI. (2026). Research Focus International Scientific Journal, 4(12), 291-297. https://doi.org/10.66073/researchfocus.v4i12.1941

Adabiyotlar

Parisi R., Symmons D.P.M., Griffiths C.E.M., Ashcroft D.M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.

Michalek I.M., Loring B., John S.M. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212.

Armstrong A.W., Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960.

Rapp S.R., Feldman S.R., Exum M.L., Fleischer A.B., Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt.1):401–407.

Kimball A.B., Jacobson C., Weiss S., Vreeland M.G., Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392.

Boehncke W.H., Schön M.P. Psoriasis. Lancet. 2015;386(9997):983–994.

Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.

Alberti K.G., Eckel R.H., Grundy S.M. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640–1645.

Grundy S.M. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364–373.

Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and metabolic syndrome: a systematic review and meta-analysis. J Am Acad Dermatol. 2013;68(4):654–662.

Gisondi P., Tessari G., Conti A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol. 2007;157(1):68–73.

Langan S.M., Seminara N.M., Shin D.B., et al. Prevalence of metabolic syndrome in patients with psoriasis: population-based study. J Am Acad Dermatol. 2012;67(5):796–804.

Mehta N.N., Azfar R.S., Reilly M.P., Gelfand J.M. Psoriasis and cardiovascular risk: mechanisms and clinical implications. Curr Opin Dermatol. 2010;17(3):302–307.

Coimbra S., Figueiredo A., Castro E., Rocha-Pereira P., Santos-Silva A. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol. 2012;51(4):389–398.

Kim J., Krueger J.G. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13–23.

Baliwag J., Barnes D.H., Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342–350.

Gisondi P., Del Giglio M., Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427.

Torres T., Puig L. Personalized medicine for psoriasis: current perspectives. Drug Des Devel Ther. 2015;9:1433–1440.